The evidence that strict glycaemic control is beneficial [4] documented in subjects with type 2 diabetes (T2DM) that strict glycaemic control (mean HbA1 c : 6.5%) in comparison with the standard control (mean HbA1 c : 7.3%) is associated with a significant reduction in renal events, including onset of or worsening of nephropathy [hazard ratio (HR) 0.79; P = 0.006], new-onset microalbuminuria (HR 0.91; P = 0.02) and, in particular, development of macroalbuminuria (HR 0.70; P < 0.001). Moreover, patients with macroalbuminuria and chronic kidney disease (CKD; eGFR 60 mL/min/ 1.73 m 2 at baseline) had a 3.2-fold higher risk for cardiovascular (CV) events and a 22.2-fold higher risk for renal events compared with patients who had neither risk factor. In a study on kidney plus pancreas transplantation in type 1 diabetic patients, Morath et al. [5] had shown that metabolic control improves long-term renal allograft and patient survival. A recent Austrian cohort study [6] of 798 first renal allograft recipients with a diagnosis of diabetes mellitus prior to transplantation also showed that glucose control was significantly associated with patient and graft survival after renal transplantation.
The evidence that strict glycaemic control is beneficial
Several large randomized controlled trials including the Diabetes Control and Complications Trial in type 1 diabetes [1] and the UK Prospective Diabetes Study [2] as well as the Kumamoto Study [3] in type 2 diabetes indicate that good glycaemic control can reduce the risk of nephropathy. More recently, the ADVANCE trial [4] documented in subjects with type 2 diabetes (T2DM) that strict glycaemic control (mean HbA1 c : 6.5%) in comparison with the standard control (mean HbA1 c : 7.3%) is associated with a significant reduction in renal events, including onset of or worsening of nephropathy [hazard ratio (HR) 0.79; P = 0.006], new-onset microalbuminuria (HR 0.91; P = 0.02) and, in particular, development of macroalbuminuria (HR 0.70; P < 0.001). Moreover, patients with macroalbuminuria and chronic kidney disease (CKD; eGFR 60 mL/min/ 1.73 m 2 at baseline) had a 3.2-fold higher risk for cardiovascular (CV) events and a 22.2-fold higher risk for renal events compared with patients who had neither risk factor. In a study on kidney plus pancreas transplantation in type 1 diabetic patients, Morath et al. [5] had shown that metabolic control improves long-term renal allograft and patient survival. A recent Austrian cohort study [6] of 798 first renal allograft recipients with a diagnosis of diabetes mellitus prior to transplantation also showed that glucose control was significantly associated with patient and graft survival after renal transplantation.
Blood glucose control is more problematic in kidney disease
Can one extrapolate that these very positive renoprotective effects of intensive glucose control are seen in all diabetic patients with CKD or end-stage renal disease (ESRD)? Unfortunately, results of prospective randomized controlled intervention studies are not yet available to answer this clinically relevant question, despite the fact that diabetes is present in 25-50% of patients with ESRD.
The evidence in CKD
Information about the effect of strict glycaemic control on outcome in diabetic patients with CKD is very limited. In the PROactive study (Prospective Pioglitazone Clinical Trial in Macrovascular Events), patients with type 2 diabetes and CKD (n = 597; 11.6% of the 5154 patients) had a particularly high CV risk and cardiovascular disease (CVD) [7] . The incidence of the combined end point (non-fatal myocardial infarction, stroke and death) was 18.3% in patients with CKD compared with 11.5% in patients without CKD (HR 1.65; P < 0.0001). In addition, all-cause mortality was 10.9% compared to 5.9% (HR 1.86) in those without CKD. Remarkably, patients who had CKD and were treated with pioglitazone were less likely to reach the combined end point (HR 0.66; P < 0.001) independently of the severity of renal impairment [7] . Since at study end the HbA1 c difference between pioglitazone and placebo was only 0.5% (6.9 vs 7.4%), presumably a variety of well-documented anti-atherogenic effects of pioglitazone [8] were responsible for CV protection in diabetic patients presenting with CVD.
The evidence in ESRD
It is well known that the 5-year survival is much lower in diabetic vs non-diabetic patients on HD [9] . During the last decade, several observational studies [10] [11] [12] [13] [14] were published indicating that the survival of diabetic patients on haemodialysis (HD) is influenced by the glycaemic control. Morioka et al. [10] evaluated the impact of glycaemic control on survival in 150 diabetic subjects with ESRD starting HD treatment. During the short follow-up period of 2.8 years, 76% of the patients died; however, in those with good control (HbA1 c < 7.5%), mortality was lower than in those with poor glycaemic control (HbA1 c ≥ 7.5%). Oomichi et al. [11] found in a 7-year observational study of 114 diabetic patients on HD that mortality was similar in patients with good HbA1 c <6.5% and fair glycaemic control (HbA1 c > 6.5% < 8.0%), but mortality was significantly higher (HR 2.89; P = 0.01) in those with poor glycaemic control (HbA1 c > 8.0%). Hayashino et al. [12] analysed mortality in the large Japanese Dialysis Out-comes and Practice Pattern Study on 1569 HD patients with diabetes and 3342 patients without diabetes. Mortality was significantly higher in diabetic patients on HD whose HbA1 c was in the fifth quintile (HbA1 c ≥ 7.3%), but was not different in the four quintiles with HbA1 c ranging from 5.0 to 7.2%.
In contrast to these studies in Asian dialysis populations, no correlation between HbA1 c and survival was found at 12 months in 24 875 US diabetic dialysis patients [15] . The failure to see a beneficial effect of glycaemic control may be explained by the underlying differences in the tools used to measure glycaemia. Kalantar-Zadeh et al. [13] evaluated 23 618 US diabetic HD patients and evaluated survival as a function of HbA1 c . He observed that higher HbA1 c values were incrementally associated with higher mortality. Compared with patients with HbA1 c in the range of 5-6%, patients with HbA1 c >10% had higher HRs of adjusted all-cause and CV death: 1.41 and 1.73 (P < 0.001), respectively. Remarkably, this relationship was only seen in patients without anaemia (Hb > 11.0 g/day; n = 19 316) and not in patients with anaemia or malnutrition. Recently, Drechsler et al. [14] investigated the impact of glycaemic control on cardiac and vascular outcomes in 1255 diabetic HD patients in the German Diabetes and Dialysis Study (4D Study). During 4 years of follow-up, patients with HbA1 c >8.0% or HbA1 c from >6 to <8% had an increased risk of sudden death (HR 1.85 and 2.26, respectively; P < 0.003) compared with patients with HbA1 c <6.0%. In contrast, the risk of myocardial infarction and all-cause mortality did not differ between the three groups.
The problems of evaluating glycaemic control in ESRD
Unfortunately, HbA1 c is not an ideal control parameter to assess glycaemic control in patients with advanced kidney disease. As early as 1979, HbA1 levels were measured in patients on HD or with CKD using ion exchange chromatography; even then, the accuracy of this method in patients with advanced CKD had been questioned [16] . In chronic renal failure, the lifespan of erythrocytes is shortened, and low HbA1 c values may therefore be artificially low because of shorter exposure of erythrocytes to glycaemia. Thus, HbA1 and HbA1 c , as indicators of long-term glycaemic control, should be interpreted with caution in patients with serum creatinine concentrations >2.5 mg/ dL [16] . Two recent studies [17, 18] confirmed that in diabetic HD patients, HbA1 c levels significantly underestimate glycaemic control, while glycated albumin reflects glycaemic control more accurately. Unfortunately, this method is not widely available. In ESRD patients, lower HbA1 c values were associated with lower haemoglobin concentration and higher doses of erythropoietin, reflecting shorter erythrocyte half-lives.
Should all diabetic patients be given the same antidiabetic treatment? Association for the Study of Diabetes consensus [19] or whether alternatively a more individualized antidiabetic approach is appropriate, taking into account pathophysiologic criteria (i.e. insulin resistance or insulin deficiency, comorbidity and risk of hypoglycaemia) [20] . Another point to consider is the cumulation of some oral antidiabetic agents or their metabolites. Furthermore, prolonged insulin half-life and low or absent renal gluconeogenesis put patients with CKD and ESRD at increased risk of severe hypoglycaemia. Therefore, aggressive glucose lowering with sulfonylureas or insulin should be avoided. Two reports from Japan [21] and Germany [22] , respectively, documented that most emergency cases with severe hypoglycaemia had significantly impaired renal function and had been treated with either sulfonylurea agents or insulin. When the outcome was analysed in a UK observational study on 90 000 type 2 diabetic patients according to the type of oral antidiabetic drug, the use of sulfonylureas was associated with significantly increased mortality (HR 1.43) compared to metformin, whereas pioglitazone (HR 0.60) was associated with significantly lower mortality when compared with metformin [23] .
Does antidiabetic treatment even increase mortality?
Two recent US observational studies [24, 25] evaluated whether the type of antidiabetic treatment is relevant to the occurrence of death in haemodialysed diabetic patients. Brunelli et al. [24] assessed in a national cohort of 5290 incident US diabetic HD patients the effect of thiazolidinedione (TZD) use on survival. TZD use was associated with significantly lower all-cause mortality in insulin-free, but not in insulin-requiring, subjects; the adjusted HRs were 0.53 (0.31-0.89) and 0.82 (0.46-1.47), respectively. In contrast, in a much smaller study [25] of 2393 diabetic HD patients, treatment with rosiglitazone (n = 177), but not with pioglitazone (n = 1 18), was associated with a higher all-cause (HR 1.38) and CV mortality (HR 1.59; P < 0.02) compared with the use of non-TZD oral hypoglycaemic agents (n = 2050). For the selection of antidiabetic drugs (Figure 1 ), the degree of renal insufficiency is very important since many antidiabetic drugs are contraindicated in advanced chronic kidney disease (e.g. metformin, sitagliptin and miglitol) or require significant dose reduction (e.g. sulfonylureas, insulin, acarbose and exenatide).
Based on the available data, we recommend a HbA1 c of 6.5-7.0% for the prevention of renal disease in diabetic patients, whereas in the advanced stages of diabetic kidney disease a higher HbA1 c of about 7.5% is acceptable on the basis of available data especially for patients with established CVD [20] . Our suggestion is supported by a very large recent UK observational study [26] of 48 000 type 2 diabetic subjects in whom a median HbA1 c of 7.5% was associated with the lowest mortality, whereas in those with a HbA1 c of 6.4% mortality was higher in individuals on oral treatment (HR 1.52) and, in particular, those on insulin treatment (HR 1.79). These alarming observations are in line with the findings of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study [27] , which showed that intensive glucose control (mean HbA1 c : 6.5%) is associated with increased all-cause and CVD mortality in comparison to conventional therapy (mean HbA1 c : 7.5%).
In conclusion, there is an urgent need for large prospective randomized studies in diabetic patients with CKD or on HD with the following goals: to compare different approaches of antidiabetic treatment and to study the efficacy and safety of different levels of glycaemic control.
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